Corbus Pharmaceuticals Holdings, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Corbus is a precision oncology and obesity-focused biotechnology company with no product revenue. Its primary pipeline includes CRB-701, a Nectin-4 antibody-drug conjugate; CRB-601, an anti-integrin monoclonal antibody; and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity. The filing covers the three months ended March 31, 2024, and was filed May 7, 2024.
- CRB-701: U.S. Phase 1 trial began dosing its first patient on April 2, 2024; the company reported preliminary China Phase 1 data showing a 43% overall response rate and 71% disease control rate among seven patients receiving potentially therapeutic doses.
- CRB-601: FDA cleared the IND in January 2024; first patient enrollment was expected in summer 2024.
- CRB-913: IND-enabling studies are underway; first Phase 1 patient treatment is expected in the first quarter of 2025.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Product revenue | $0 | $0 | No change |
| Research and development expense | $5.8 million | $13.4 million | Down $7.6 million |
| General and administrative expense | $3.9 million | $3.9 million | Down $0.05 million |
| Total operating expenses | $9.6 million | $17.3 million | Down $7.7 million |
| Operating loss | $9.6 million | $17.3 million | Improved |
| Other income/(expense), net | $2.7 million | $(0.4) million | Improved $3.2 million |
| Net loss | $6.9 million | $17.7 million | Improved $10.8 million |
| Basic and diluted net loss per share | $0.83 loss | $4.24 loss | Improved |
| Net cash used in operating activities | $8.0 million | $15.1 million | Improved $7.1 million |
Gross margin and operating margin are not meaningful because the company has no product revenue. Other income included approximately $2.5 million of refundable foreign research and development tax credits and higher investment income.
- Cash and cash equivalents at March 31, 2024: $14.1 million.
- Investments: $106.0 million; restricted cash: $0.7 million.
- Total cash, cash equivalents, investments, and restricted cash: approximately $120.8 million.
- Working capital: approximately $95.8 million, based on current assets of $121.7 million and current liabilities of $25.9 million.
- Accumulated deficit: approximately $443.6 million.
- Current portion of long-term debt: $12.8 million; principal and final payment obligations under the K2 loan totaled approximately $14.6 million and mature in 2024.
Material changes versus the prior comparable period
- R&D expense declined primarily because Q1 2023 included a $7.5 million CRB-701 upfront license payment and a $1.2 million UCSF development milestone. The decrease was partially offset by increased CRO costs as the U.S. CRB-701 trial began.
- Net loss improved by approximately $10.8 million, aided by lower R&D spending and higher other income.
- Operating cash use decreased by approximately $7.1 million.
- The company raised substantial equity capital: approximately $21.1 million of gross ATM proceeds and approximately $94.5 million of gross proceeds from a February public offering, which generated $88.6 million of net proceeds.
- Shares outstanding increased to 10.5 million at March 31, 2024 from 4.4 million at December 31, 2023, primarily due to equity financing. K2 converted $1.125 million of debt into 142,857 shares.
- Stockholders’ equity increased from a $6.9 million deficit at December 31, 2023 to $97.0 million at March 31, 2024.
- The company gave notice terminating the Milky Way license agreement effective July 23, 2024.
- Nasdaq notified the company on February 8, 2024 that it had regained compliance with the applicable continued-listing standard based on market value of listed securities.
Guidance, outlook, risks, contingencies, and unusual items
- Management expects continuing operating losses for the foreseeable future and does not expect product revenue unless and until a product candidate is successfully developed and approved.
- The filing states that cash, cash equivalents, and investments of approximately $120.1 million were expected to fund operations and capital requirements for at least 12 months from issuance. The MD&A separately states that, based on current planned expenditures, these resources are expected to support operations through the first quarter of 2027.
- Additional financing will be required to fund clinical development and other operations. Financing may be unavailable or available only on unfavorable terms, and equity or convertible financings could dilute existing holders.
- The K2 secured loan matures August 1, 2024, bears interest at 13.75% as of March 31, 2024, and is secured by substantially all company assets. The company was in compliance with its covenants at quarter-end.
- Accrued license costs totaled $4.5 million, including $2.5 million due to CSPC in August 2024 and $2.0 million of UCSF milestone obligations due in 2024.
- Potential future license payments are substantial, including up to $130.0 million in development and regulatory milestones and $555.0 million in commercial milestones under the CSPC agreement, and up to $153.2 million in UCSF development and regulatory milestones, excluding certain indication milestones.
- From April 1, 2024 through the filing date, the company sold 311,893 additional ATM shares for approximately $12.3 million of gross proceeds, less approximately $0.4 million of issuance costs.
- Management identified continuing risks related to clinical-trial execution, regulatory approval, intellectual-property protection, additional capital needs, competition, retention of key personnel, and the company’s history of operating losses.
- No material legal proceedings were reported, and management stated that disclosure controls were effective with no material changes in internal control over financial reporting.
Important facts for investors to verify
- Reconcile the stated liquidity runway through Q1 2027 with the separate disclosure describing funding sufficient for at least 12 months.
- Monitor repayment or refinancing of the approximately $14.6 million K2 obligation due in 2024 and the effect of the debt conversion on dilution.
- Verify enrollment, safety, response data, and regulatory progress for the CRB-701 and CRB-601 Phase 1 programs.
- Track additional ATM sales, the $150 million shelf capacity, share-count growth, and resulting dilution.
- Assess the timing and cash impact of the $4.5 million accrued license obligations and the termination of the Milky Way agreement.
- Confirm whether foreign R&D tax credits and investment income are recurring; these items materially improved Q1 2024 results but may not repeat at the same level.